Is FAST FORWARD the Way Forward in Radiotherapy for Locally Advanced Breast Cancer – Learnings From the COVID Pandemic
Clinical Breast Cancer · 2024-04 · 24 (3) · e116-e125
DOI: 10.1016/j.clbc.2023.11.003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Breast Cancer, 2024-04. Verfasst von Prashanth Giridhar und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, MPMMCC/ HBCH, Tata Memorial Centre, Varanasi, Uttar Pradesh, India. Electronic address: Prashanth.jipmer@gmail.com. Hauptthemen laut MEDLINE: Breast Neoplasms, COVID-19, Esophagitis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 26 Literaturangaben.
Abstract (Originalsprache)
INTRODUCTION: Low middle-income countries (LMICs), including India, have paucity of external beam radiotherapy (RT) machines leading to prolonged wait times for RT. Delay in delivery of RT has been shown to adversely affect outcomes in locally advanced breast cancer (LABC). With the availability of results of multiple randomized controlled trials, hypofractionated RT delivered over 3 to 4 weeks became the standard of care in breast cancer RT. METHODS: We conducted a retrospective audit of 172 LABC patients treated with ultrahypofractionated adjuvant RT (radiotherapy completed in 1 week) during the COVID pandemic. Log rank and Cox-regression model used for univariate and multi-variate analyses. RESULTS: No patient developed grade 3 esophagitis. Grade 2 esophagitis requiring short term narcotic analgesics was seen in 12 (6.9%) patients. Grade 2 or higher toxicity peaked between 2 and 3 weeks after RT. The estimated 2 and 3- year recurrence free survival (RFS) for the cohort is 87.1 % and 81.4 %, respectively. The estimated 2 and 3-year overall survival for the cohort is 95% and 91.3%. On multivariate analysis, presence of extra-nodal extension was found to be an independent factor associated with worse RFS (P = .028). CONCLUSIONS: FAST FORWARD protocol RT in LABC appears well tolerated.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, MPMMCC/ HBCH, Tata Memorial Centre, Varanasi, Uttar Pradesh, India. Electronic address: Prashanth.jipmer@gmail.com.
- Department of Radiation Oncology, MPMMCC/ HBCH, Tata Memorial Centre, Varanasi, Uttar Pradesh, India.
- Department of Surgical Oncology, MPMMCC/ HBCH, Tata Memorial Centre, Varanasi, Uttar Pradesh, India.
- Department of Nuclear Medicine, MPMMCC/ HBCH, Tata Memorial Centre, Varanasi, Uttar Pradesh, India.
- Department of Onco-pathology, MPMMCC/ HBCH, Tata Memorial Centre, Varanasi, Uttar Pradesh, India.
- Department of Medical Oncology, MPMMCC/ HBCH, Tata Memorial Centre, Varanasi, Uttar Pradesh, India.
Zitieren
APA
Giridhar, P., Pradhan, S., Pujari, L., Singh, P., Shinghal, A., Khandelwal, C., Mukherjee, C., Tripathi, M., Shukla, V., M V, M., Choudary, Z., & Gupta, A. (2024). Is FAST FORWARD the Way Forward in Radiotherapy for Locally Advanced Breast Cancer – Learnings From the COVID Pandemic. Clinical Breast Cancer, 24(3), e116-e125. https://doi.org/10.1016/j.clbc.2023.11.003
Vancouver
Giridhar P, Pradhan S, Pujari L, Singh P, Shinghal A, Khandelwal C, et al. Is FAST FORWARD the Way Forward in Radiotherapy for Locally Advanced Breast Cancer – Learnings From the COVID Pandemic. Clinical Breast Cancer. 2024;24(3):e116-e125. doi:10.1016/j.clbc.2023.11.003
BibTeX
@article{Giridhar2024,
author = {Giridhar, Prashanth and Pradhan, Satyajit and Pujari, Lincoln and Singh, Prarabdh and Shinghal, Abhishek and Khandelwal, Chaturbhaj and Mukherjee, Chandrima and Tripathi, Mayank and Shukla, Varun and M V, Manikandan and Choudary, Zacchariah and Gupta, Anuj},
title = {Is FAST FORWARD the Way Forward in Radiotherapy for Locally Advanced Breast Cancer – Learnings From the COVID Pandemic},
journal = {Clinical Breast Cancer},
year = {2024},
volume = {24},
number = {3},
pages = {e116--e125},
doi = {10.1016/j.clbc.2023.11.003}
}
EUVIMED